Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)

The American Journal of Cardiology
Emmanouil S BrilakisEugene Braunwald

Abstract

We examined the effects of intensive statin therapy in patients with acute coronary syndromes (ACSs) and previous coronary artery bypass graft surgery (CABG) participating in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE-IT TIMI 22) and the Aggrastat to Zocor (A to Z) trials. Of the 8,655 patients enrolled in PROVE IT-TIMI 22 or A to Z, 640 (7.4%) had undergone CABG before enrollment. After a median follow-up of 2 years, compared with patients without previous CABG, those with previous CABG had a higher risk of cardiovascular death (6.2% vs 2.8%), myocardial infarction (14.2% vs 6.6%), and readmission for ACS (7.9% vs 4.4%, p <0.001 for all comparisons) but a lower rate of repeat coronary revascularization (22.7% vs 26.9%, p = 0.01). Compared with moderate statin therapy, intensive statin therapy appeared to decrease the composite of cardiovascular death, myocardial infarction, stoke, and readmission for an ACS (A to Z primary end point) to a similar extent in patients with (26.1% vs 21.6%, hazard ratio 0.84, p = 0.27) and without (13.9% vs 12.0%, hazard ratio 0.86, p = 0.016) previous CABG, although the decrease was not statistically significant in the previous...Continue Reading

References

Oct 1, 1988·Journal of the American College of Cardiology·A WisemanP Théroux
Dec 1, 1987·Controlled Clinical Trials·D H BlankenhornR H Selzer
Sep 1, 1986·The American Journal of Cardiology·D D WatersP Théroux
Jul 1, 1996·Journal of the American College of Cardiology·P P de JaegereP W Serruys
Dec 12, 2002·Journal of the American College of Cardiology·Douglass A MorrisonUNKNOWN Investigators of the Department of Veterans Affairs Cooperative Study #385, Angina With Extremely Serious Operative Mortalit
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Mar 31, 2004·The American Journal of Cardiology·Stephen J ServossUNKNOWN PRISM-PLUS trial
Jan 18, 2005·Journal of the American College of Cardiology·Karen OkrainecMark J Eisenberg
Apr 22, 2005·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Oct 19, 2006·International Journal of Cardiology·Enrique P GurfinkelUNKNOWN GRACE Investigators
May 17, 2008·Journal of the American College of Cardiology·Sanjiv J ShahJohn C LaRosa

❮ Previous
Next ❯

Citations

Aug 14, 2009·Expert Opinion on Drug Safety·Alexander Kulik, Marc Ruel
Jul 6, 2013·The American Journal of Cardiology·Kyohei YamajiUNKNOWN j-Cypher Registry Investigators
Jun 3, 2015·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Nagendra R PokalaEmmanouil S Brilakis
Dec 14, 2011·Heart, Lung & Circulation·Ying Yan ZhuBrian F Buxton
Jun 18, 2011·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Emmanouil S Brilakis, Subhash Banerjee
Jan 28, 2010·American Heart Journal·Esam ElbarasiUNKNOWN Canadian Global Registry of Acute Coronary Events (GRACE/expanded-GRACE) Investigators
Aug 30, 2016·European Heart Journal·Alon EisenUNKNOWN IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators
Oct 9, 2014·European Heart Journal. Acute Cardiovascular Care·Rogério TeixeiraBernard J Gersh
Feb 14, 2015·Circulation·Alexander KulikUNKNOWN American Heart Association Council on Cardiovascular Surgery and Anesthesia
Apr 14, 2017·Circulation. Cardiovascular Interventions·Judit Karacsonyi, Emmanouil S Brilakis
Apr 24, 2014·Expert Review of Cardiovascular Therapy·Rafid Fayadh Al-Aqeedi, Jassim Al Suwaidi
Sep 22, 2011·Current Opinion in Cardiology·Alexander Kulik, Marc Ruel
Dec 6, 2019·Cardiology in Review·David Collins, Sheldon Goldberg
Jan 28, 2020·Cardiology in Review·Ayush MotwaniThierry H Le Jemtel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.